Fundraising FoxThird Rock Ventures — 2018 Investments
5 investments dated 2018 · listed companies and verified rows first · show all
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.
BiotechSouth San Francisco, US
Bernard Coulie(Executive Officer, Director)inJohannes Hull(Executive Officer)Eric Lefebvre(Executive Officer)inKeith Cummings(Chief Financial Officer)inLily Cheung(Chief Human Resources Officer)inMinnie Kuo(Chief Operating Officer)in
Board seatCharles HomcyNeil Exter· per SEC Form D · $62.1M raise · filed Jul 2018
Co-investorsMenlo VenturesAgent Capital
Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.
BiotechHealthtechMedical DevicesRedwood City, US
Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)
Board seatNeil ExterBarbara Weber· per SEC Form D
Co-investorsBain Capital Life SciencesForesite CapitalGen CapitalGV (Google Ventures)Illinois VenturesNextech Invest+2 more
BiotechCambridge, US
Gad Soffer(Executive Officer)Ryan Cohlhepp(Executive Officer)J. Duncan Higgons(Director)Jeffrey Bluestone(Director)Dan Matloff(Executive Officer)Sanjay Keswani(Executive Officer, Director)
Board seatAbbie CelnikerCary Pfeffer· per SEC Form D
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Eleven BiotherapeuticsKaruna Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.